AavantiBio and Catalent have announced a partnership to support the development and manufacturing of AavantiBio’s gene therapies, including its lead program in Friedreich’s Ataxia (FA).
Catalent will provide process development and CGMP manufacturing of the adeno-associated viral (AAV) vector-based therapeutic candidate for use in clinical trials in the US and Europe. The company will further support process optimisation and look to reduce material timelines at its development centre in Baltimore, Maryland.
“We look forward to working with Catalent on the development of our differentiated pipeline of innovative gene transfer therapies, focused initially on our FA program,” said Bo Cumbo, President and CEO of AavantiBio.
"Catalent is committed to partnering early with innovative companies and facilitating the development and optimization of robust, scalable manufacturing solutions," commented Manja Boerman, PhD, President, Catalent Cell & Gene Therapy. “Our development team at the University of Maryland BioPark is focused on providing process optimization services to meet our customers’ needs and partnering with them to bring innovative therapies to patients faster.”
Catalent has facilities for the production of plasmid DNA and cell and gene therapies in Maryland and Texas, US, and in Gosselies, Belgium.
